ANL (Adlai Nortye) Research & Development: $32.83 Mil (TTM As of Dec. 2025)


What is Adlai Nortye Research & Development?

Adlai Nortye ANL -1.57% Research & Development is $32.83 Mil as of Dec. 2025. The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Adlai Nortye's Research & Development for the six months ended in Dec. 2025 was $17.59 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $32.83 Mil.

Adlai Nortye  (NAS:ANL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Adlai Nortye Research & Development Related Terms

Adlai Nortye Research & Development Historical Data

* Premium members only.

The historical data trend for Adlai Nortye's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adlai Nortye Research & Development Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
42.11 54.49 58.15 44.92 32.83

Adlai Nortye Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only 30.91 26.02 18.90 15.25 17.59

Adlai Nortye Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $32.83 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $32.83 Mil mean?
Adlai Nortye (ANL) has a Research & Development of $32.83 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Adlai Nortye and its competitors.
Is Adlai Nortye's Research & Development too high?
Adlai Nortye's current Research & Development is $32.83 Mil.
How does Adlai Nortye's Research & Development compare to PHAT and AURA?
Adlai Nortye's Research & Development of $32.83 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Adlai Nortye and its competitors. Adlai Nortye's current Research & Development is $32.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current Research & Development of $32.83 Mil. The current Research & Development is $32.83 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Adlai Nortye (ANL), the current Research & Development is $32.83 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adlai Nortye Business Description

Other Exchanges N2U0:Germany
Address 685 US Highway 1, New Jersey Biotechnology Development Center, 2nd Floor, North Brunswick, NJ, USA, 08902
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.